Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label Clinical Study of Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-Muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment

NCT06766266 is registered in ClinicalTrials.gov with First Affiliated Hospital of Chongqing Medical University as lead sponsor.

NCT NCT06766266
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06766266 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label Clinical Study of Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-Muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment
Lead sponsor
First Affiliated Hospital of Chongqing Medical University
Phase
Phase 1
Overall status
Recruiting
Start date
January 10, 2025
Completion date
December 24, 2025
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle invasive bladder urothelial carcinoma